Reisa Sperling neurologist
Sperling, Reisa
VIAF ID: 36692715 (Personal)
Permalink: http://viaf.org/viaf/36692715
Preferred Forms
-
100 0 _
‡a
Reisa Sperling
‡c
neurologist
-
100 1 _
‡a
Sperling, Reisa
-
100 1 _
‡a
Sperling, Reisa
4xx's: Alternate Name Forms (1)
Works
| Title | Sources |
|---|---|
| The ADNI Publication Policy: commensurate recognition of critical contributors who are not authors |
|
| Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. |
|
| Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials |
|
| Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent? |
|
| Assessment of cognition in early dementia. |
|
| Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. |
|
| Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. |
|
| Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies |
|
| Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study |
|
| Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. |
|
| Defeating Alzheimer's disease and other dementias: a priority for European science and society. |
|
| Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. |
|
| Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants |
|
| Epicenters of dynamic connectivity in the adaptation of the ventral visual system. |
|
| The evolution of preclinical Alzheimer's disease: implications for prevention trials. |
|
| Functional MRI detection of pharmacologically induced memory impairment. |
|
| Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. |
|
| Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. |
|
| Implementation of subjective cognitive decline criteria in research studies. |
|
| In vivo characterization of the early states of the amyloid-beta network. |
|
| Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease |
|
| Inflammatory cerebral amyloid angiopathy and amyloid-modifying therapies: variations on the same ARIA? |
|
| Mapping the road forward in Alzheimer's disease. |
|
| NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. |
|
| On the path to 2025: understanding the Alzheimer's disease continuum. |
|
| Potential of functional MRI as a biomarker in early Alzheimer's disease |
|
| Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. |
|
| Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. |
|
| Pro: Can biomarkers be gold standards in Alzheimer's disease? |
|
| Putting names to faces: successful encoding of associative memories activates the anterior hippocampal formation |
|
| Reliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults. |
|
| Research priorities to reduce the global burden of dementia by 2025. |
|
| The role of neuroimaging in elucidating delirium pathophysiology. |
|
| Scientific American frontiers. Don't forget! [VR] c2005: |
|
| Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease |
|
| Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. |
|
| Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain. |
|
| Tau positron emission tomographic imaging in aging and early Alzheimer disease |
|
| Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. |
|
| To sleep, perchance to delay dementia. |
|
| Two macroscopic and microscopic brain imaging studies of human hippocampus in early Alzheimer's disease and schizophrenia research. |
|
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. |
|
| Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia. |
|
